New Insights into the Mechanisms of Gastric Cancer Multidrug Resistance and Future Perspectives
Authors:
- 7 April 2010
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 6 (4) , 527-537
Abstract
Gastric cancer is still the second leading cause of cancer death worldwide. Chemotherapy is one of the major treatment options for advanced gastric cancer. The efficacy of chemotherapy for gastric cancer is poor due to insensitivity and the development of multidrug resistance (MDR). Gastric cancer MDR involves a large number of molecules and complex mechanisms. Classical drug-resistant molecules, such as P-glycoprotein/ABCB1 and MRP1/ABCC1, have been found to play important roles in mediating MDR in some gastric cancers. In recent years, new molecules and mechanisms have been found to be associated with the development of gastric cancer MDR and might provide new targets for tackling gastric cancer MDR. Combined use of molecularly targeted therapy with chemotherapy may offer improved outcomes for gastric cancer patients and might provide new threads of hope for gastric cancer treatment.Keywords
This publication has 73 references indexed in Scilit:
- Gastric cancer in the era of molecularly targeted agents: current drug development strategiesJournal of Cancer Research and Clinical Oncology, 2009
- Optimising treatment regimens for the management of advanced gastric cancerAnnals of Oncology, 2009
- Epidemiology of Stomach Cancer2009
- Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancerBritish Journal of Surgery, 2009
- Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenaseAnti-Cancer Drugs, 2008
- Gastric Cancer: Pathogenesis, Screening, and TreatmentGastrointestinal Endoscopy Clinics of North America, 2008
- Surgery and adjuvant chemotherapyInternational Journal of Clinical Oncology, 2008
- Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapyOncogene, 2007
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resectionBritish Journal of Cancer, 2001